Previous Article | Next Article ![]()
Infect. Immun., 04 1996, 1203-1207, Vol 64, No. 4
F Grassi, C Perronne, M Levacher-Clergeot, Y Cohen, C Maslo, F Chau, M Sinet and JJ Pocidalo
The murine leukemia virus LP-BM5 has been used to reproduce the model of
murine AIDS in order to evaluate the course of infection with the MO- 1
strain of Mycobacterium avium complex (MAC). LP-BM5 was inoculated in
C57BL/6 mice by intravenous (i.v.) injection either 8 weeks before an i.v.
challenge with 10(3) or 10(6) CFU of MAC (coinfection 1) or 10 days after
an i.v. challenge with 10(3) CFU of MAC (coinfection 2). During coinfection
2 experiments, the phenotypic alterations in blood lymphocyte subsets were
analyzed. During coinfection 1, LP-BM5 infection tended to decrease the
mycobacterial growth, with the difference reaching statistical significance
for the lower inoculum (10(3) CFU of MAC) (P<0.001).During coinfection
2, LP-BM5 did not exacerbate MAC infection except in the spleen, at day 90
after LP-BM5 challenge (P<0.001). LP-BM5 infection and the LP-BM5-MAC
coinfection increased the numbers of activated CD4+ lymphocytes (CD4+
Ly6AE+) (P<0.001), activated CD8+ lymphocytes (CD8+ Ly6AE+)
(P<0.001), and activated B lymphocytes (Ly5+ Ly6AE+) (P<0.001). This
activation of T lymphocytes could explain the lack of exacerbation of MAC
infection and even the trend to a lower level of MAC infection. Thus, this
model of retroviral infection of mice does not seem to be a reliable model
of immunodepression for the study of MAC infection and its treatments.
Copyright © 1996, American Society for Microbiology
Mycobacterium avium complex infection in mice: lack of exacerbation after LP-BM5 murine leukemia virus infection
Service des Maladies Infectieuses et Tropicales, Hopital Raymond Poincare, Garches, France.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|